Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries

Primary Care Diabetes

Volumn 9, Issue 1, 2015, Pages 39-47

  Sabale, Ugne ^a   Ekman, Mattias ^a   Granström, Ola ^a,d   Bergenheim, Klas ^a   McEwan, Phil ^b,c  

^a ASTRAZENECA R AND D   (Sweden)

^b HEALTH ECONOMICS AND OUTCOMES RESEARCH LTD   (United Kingdom)

^c SWANSEA UNIVERSITY   (United Kingdom)

^d GILEAD SCIENCES   (United States)

Author keywords

Cost effectiveness; Dapagliflozin; Economic modeling; Sulfonylurea; Type 2 diabetes mellitus

Indexed keywords

DAPAGLIFLOZIN; GLIPIZIDE; HEMOGLOBIN A1C; ISOPHANE INSULIN; METFORMIN; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; SULFONYLUREA DERIVATIVE;

ADD ON THERAPY; ADULT; ARTICLE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DENMARK; DRUG COST; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FINLAND; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORWAY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SIMULATION; SWEDEN; TREATMENT DURATION; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION; BLOOD; COMPARATIVE STUDY; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; ECONOMICS; SCANDINAVIA; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

BENZHYDRYL COMPOUNDS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG COSTS; DRUG THERAPY, COMBINATION; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; SCANDINAVIAN AND NORDIC COUNTRIES; SULFONYLUREA COMPOUNDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84920669160     PISSN: 17519918     EISSN: 18780210     Source Type: Journal    
DOI: 10.1016/j.pcd.2014.04.007     Document Type: Article

References (34)

1. M. Bogelund, T. Vilsboll, J. Faber, J.E. Henriksen, R.P. Gjesing, and M. Lammert Patient preferences for diabetes management among people with type 2 diabetes in Denmark - a discrete choice experiment Curr. Med. Res. Opin. 27 November (11) 2011 2175 2183
2. A.P. Yu, E.Q. Wu, H.G. Birnbaum, S. Emani, M. Fay, and G. Pohl Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data Curr. Med. Res. Opin. 23 September (9) 2007 2157 2169
3. P. Zhang, X. Zhang, J. Brown, D. Vistisen, R. Sicree, and J. Shaw Global healthcare expenditure on diabetes for 2010 and 2030 Diabetes Res. Clin. Pract. 87 March (3) 2010 293 301
4. UKPDS 33 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lancet 352 September (9131) 1998 837 853
5. NICE Type 2 diabetes: the management of type 2 diabetes NICE Clinical Guideline 87 2009, May National Institute for Health and Clinical Excellence
6. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, and M. Nauck Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia 55 June (6) 2012 1577 1596
7. L.S. Matza, K.S. Boye, N. Yurgin, J. Brewster-Jordan, S. Mannix, and J.M. Shorr Utilities and disutilities for type 2 diabetes treatment-related attributes Qual. Life Res. 16 September (7) 2007 1251 1265
8. C.J. Currie, C.L. Morgan, C.D. Poole, P. Sharplin, M. Lammert, and P. McEwan Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes Curr. Med. Res. Opin. 22 August (8) 2006 1523 1534
9. J.W. Anderson, C.W. Kendall, and D.J. Jenkins Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies J. Am. Coll. Nutr. 22 October (5) 2003 331 339
10. A.L. Peters Patient and treatment perspectives: revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk Cleve. Clin. J. Med. 76 December (Suppl. 5) 2009 S20 S27
11. J. Bodegard, J. Sundstrom, B. Svennblad, C.J. Ostgren, P.M. Nilsson, and G. Johansson Changes in body mass index following newly diagnosed type 2 diabetes and risk of cardiovascular mortality: a cohort study of 8486 primary-care patients Diabetes Metab. 39 September (4) 2013 306 313
12. K. Bolin, C. Gip, A.C. Mork, and B. Lindgren Diabetes, healthcare cost and loss of productivity in Sweden 1987 and 2005 - a register-based approach Diabet. Med. 26 September (9) 2009 928 934
13. F.X. Pi-Sunyer The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus Postgrad. Med. 121 September (5) 2009 94 107
14. S.A. Ross, G. Dzida, J. Vora, K. Khunti, M. Kaiser, and R.J. Ligthelm Impact of weight gain on outcomes in type 2 diabetes Curr. Med. Res. Opin. 27 July (7) 2011 1431 1438
15. M.A. Nauck, S. Del Prato, J.J. Meier, S. Duran-Garcia, K. Rohwedder, and M. Elze Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial Diabetes Care 34 September (9) 2011 2015 2022
16. O. Granstrom, K. Bergenheim, P. McEwan, K. Sennfalt, and M. Henriksson Cost-effectiveness of saxagliptin (Onglyza(R)) in type 2 diabetes in Sweden Prim. Care Diabetes 6 July (2) 2012 127 136
17. Mount Hood 4 Modeling Group Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting Diabetes Care 30 June (6) 2007 1638 1646
18. P.M. Clarke, A.M. Gray, A. Briggs, A.J. Farmer, P. Fenn, and R.J. Stevens A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68) Diabetologia 47 October (10) 2004 1747 1759
19. J. Lundkvist, C. Berne, B. Bolinder, and L. Jönsson The economic and quality of life impact of hypoglycemia Eur. J. Health Econ. 50 2005 197 202
20. N. Waugh, E. Cummins, P. Royle, C. Clar, M. Marien, and B. Richter Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation Health Technol. Assess. 14 July (36) 2010 1 248
21. U.G. Gerdtham, P. Clarke, A. Hayes, and S. Gudbjornsdottir Estimating the cost of diabetes mellitus-related events from inpatient admissions in Sweden using administrative hospitalization data Pharmacoeconomics 27 1 2009 81 90
22. F. Henriksson Applications of economic models in healthcare: the introduction of pioglitazone in Sweden Pharmacoeconomics 20 Suppl. 1 2002 43 53
23. W.C. Stewart, J.A. Stewart, and M.A. Mychaskiw Cost-effectiveness of latanoprost and timolol maleate for the treatment of glaucoma in Scandinavia and the United Kingdom, using a decision-analytic health economic model Eye (Lond.) 23 January (1) 2009 132 140
24. B. Schwarz, M. Gouveia, J. Chen, G. Nocea, K. Jameson, and J. Cook Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy Diabetes Obes. Metab. 10 June (Suppl. 1) 2008 43 55
25. L. Jonsson, B. Bolinder, and J. Lundkvist Cost of hypoglycemia in patients with Type 2 diabetes in Sweden Value Health 9 May-June (3) 2006 193 198
26. P. Clarke, A. Gray, and R. Holman Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62) Med. Decis. Making 22 July-August (4) 2002 340 349
27. S. Lane, A. Levy, J. Sambrook, J. Mukherjee, M. Leahy, and H. Tildesley The impact on utilities of weight loss and weight gain among Canadian patients with type 2 diabetes Value Health 15 4 2012 A183
28. S.L. Dennett, K.S. Boye, and N.R. Yurgin The impact of body weight on patient utilities with or without type 2 diabetes: a review of the medical literature Value Health 11 May-June (3) 2008 478 486
29. J.P. Wilding, V. Woo, N.G. Soler, A. Pahor, J. Sugg, and K. Rohwedder Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial Ann. Intern. Med. 156 March (6) 2012 405 415
30. R.R. Wing, W. Lang, T.A. Wadden, M. Safford, W.C. Knowler, and A.G. Bertoni Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes Diabetes Care 34 July (7) 2011 1481 1486
31. C. Fajardo Montanana, C. Hernandez Herrero, and M. Rivas Fernandez Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial Diabet. Med. 25 August (8) 2008 916 923
32. C.J. Currie, P. McEwan, J.R. Peters, T.C. Patel, and S. Dixon The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects Value Health 8 September-October (5) 2005 581 590
33. H.C. Barry, M.H. Ebell, and J. Hickner Evaluation of suspected urinary tract infection in ambulatory women: a cost-utility analysis of office-based strategies J. Fam. Pract. 44 January (1) 1997 49 60
34. J.J. Caro, I.O. Stillman, A. Danel, D. Getsios, and P. McEwan Cost effectiveness of rimonabant use in patients at increased cardiometabolic risk: estimates from a Markov model J. Med. Econ. 10 2007 239 254